TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03644758

Intervention type: DIAGNOSTIC_TEST
Intervention: socio-demographic data and personal medical history
Description: Socio-demographic data and personal medical history is a self-administered questionnaire.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire. This score evaluates sleep disturbances.

Intervention type: DIAGNOSTIC_TEST
Intervention: Epworth Sleepiness Scale
Description: Epworth Sleepiness Scale is a self-administered questionnaire. This score evaluates excessive drowsiness.

Intervention type: DIAGNOSTIC_TEST
Intervention: Insomnia Severity Index (ISI)
Description: Insomnia Severity Index (ISI) is a self-administered questionnaire. This score evaluates insomnia severity.

Intervention type: DIAGNOSTIC_TEST
Intervention: stop-BANG questionnaire
Description: Stop-BANG is a self-administered questionnaire. This score evaluates Obstructive Sleep Apnea (OSA).
Study: NCT02853773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ingestion of a test meal with sweetener
Description: participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with artificially sweetened drinks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ingestion of a test meal with sweetener
Description: participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with sugary drinks drinks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ingestion of a test meal with water
Description: participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with waters
Study: NCT03191032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early sensory re-education of the hand with a sensor glove model
Description: Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
Study: NCT02438397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: premix insulin
Description: Premix-insulin(human insulin or analog) treatment will continue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: premix insulin
Description: Premix-insulin(human insulin or analog) treatment will continue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 500 mg tid by Merck

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: 100mg tid by Bayer
Study: NCT03858231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5Mg-325Mg Tablet
Description: 1 tablet up to 4 times per day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: 1 tablet up to 4 times per day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 325Mg Tab
Description: 1 tablet up to 4 times per day for 7 days
Study: NCT01210573

Intervention type: DEVICE
Intervention: adjustment of LVAD or pacemaker
Description: For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.~For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.
Study: NCT00573365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentlewaves Select™ handheld high energy LED array
Description: LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: Weekly radiation treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Weekly radiation treatment
Study: NCT04526327

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: the combination of aerobic and resistive exercise, three time a week
Study: NCT01158703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel 75mg daily by mouth daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: sugar pill by mouth daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
Study: NCT00542971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 12 mg/m\^2 IV over 1 hour daily (days 1-3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose 400 mg by mouth for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 1.5 g/m\^2 IV over 24 hours daily (days 1-4)
Study: NCT00767715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol
Description: physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zuclopentixol
Description: physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
Study: NCT02800759

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: JOINTRUS®
Description: 100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 80% dose of JOINTRUS®
Description: 80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 62.4% dose of JOINTRUS®
Description: 62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Starch 100%
Description: 0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
Study: NCT00901927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Starting dose 90 mg/m\^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m\^2 by vein over 15 minutes on Day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein over several hours on Day 1 of each cycle.
Study: NCT02780609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 100 mg/m\^2 IV over 30-45 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Cell Transplantation (HCT)
Description: Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Fosaprepitant at 150 mg IV on days -3 and -2.
Study: NCT01008631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: 6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: 6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
Study: NCT02942420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bucillamine
Description: Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bucillamine
Description: Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
Study: NCT03190174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Rapamycin
Description: Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m2; at Dose Level 2, 3-6 six patients will receive 75 mg/m2; and at Dose Level 3, 3-6 patients will receive 100 mg/m2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A defined dose of nivolumab, 3 mg/kg, will be given IV over 30 minutes q 3 weeks
Study: NCT02333851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixtard 30:70 Novonordisk® twice daily
Description: Premixed insulin twice daily before breakfast and before dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus® once daily and Apidra® before meals
Description: Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
Study: NCT01732575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enrichment with meaning-generating activities
Description: Gaps in the rehabilitation are identified by staff and researchers in dialogue. Staff gets relevant education. An intervention is tailored by staff and researchers to bridge the gaps. Consumers have a say and the intervention is revised accordingly. The intervention is implemented and continues for 14 months.
Study: NCT03700255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PickUpSimTM simulation training program
Description: The residents will take part in simulation sessions of 30 minutes duration. There will be 4 training sessions with seven simulation scenarios available. During the sessions, the following data will be collected for each scenario success or failure, reason for failure, time needed for completion, and oocyte retrieval rate. All scenarios will be repeated in the same conditions in the second week and data collected again. In the following 15 days, residents will start performing OPU, under direct supervision from senior physicians. For each patient, the resident will puncture one ovary. During the retrieval, the operator will specify the number of follicles punctured for each collected tube. The identity of the operator and the number of follicles punctured (per tube and in total) are noted on a separate sheet entitled the retrieval sheet. After the first month, residents will start performing all the OPUs, including both ovaries, supervised by the senior physicians.
Study: NCT01536262

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium + Olodaterol
Description: Tiotropium and Olodaterol FDC once daily inhalation

Intervention type: DEVICE
Group type: OTHER
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium + Olodaterol
Description: Tiotropium and Olodaterol FDC once daily inhalation

Intervention type: DRUG
Group type: OTHER
Intervention: Olodaterol
Description: Olodaterol once daily inhalation

Intervention type: DEVICE
Group type: OTHER
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: OTHER
Intervention: Respimat
Description: Respimat inhaler
Study: NCT03609580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin - 1 week
Description: The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 matching placebo capsules
Description: Oral capsules
Study: NCT03609580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin - 3 days
Description: The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 3 days), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
Study: NCT02466737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no axillary surgery versus SLNB
Description: in cases with newly diagnosed breast cancer and clinically negative axillary status
Study: NCT00465361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: performance feedback with an educational module
Description: individual performance feedback with an educational module
Study: NCT04520243

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual acuity assessment by ETDRS charts
Description: All participants must complete VA measurement of both eyes using 2 charts including the ETDRS letters chart and ETDRS numbers chart.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual acuity assessment by ETDRS charts
Description: All participants must complete VA measurement of both eyes using 2 charts including the ETDRS letters chart and ETDRS numbers chart.
Study: NCT03789487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device programming of CRT pacemaker or defibrillator
Description: Stimulation vector optimization then AV delay optimization in order to obtain the highest systolic blood pressure (SBP) by using the Finapress® NOVA noninvasive device
Study: NCT03595241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation by implanted device.
Description: Spinal cord stimulation (SCS) protocol from the implanted device. This involves activation of the device for the (SCS) protocol including Burst DR therapy.
Study: NCT01118767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell phone intervention
Description: Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
Study: NCT02466737

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no axillary surgery versus SLNB
Description: in cases with newly diagnosed breast cancer and clinically negative axillary status

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLNB versus completion ALND
Description: in cases with 1-3 macrometastases in sentinel lymph nodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLNB versus completion ALND
Description: in cases with 1-3 macrometastases in sentinel lymph nodes
Study: NCT02769481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: 20 mg, tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Bexagliflozin
Description: inactive tablet to match active comparator bexagliflozin
Study: NCT03210181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block
Description: A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive an equivalent volume of normal saline
Study: NCT02981810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55*
Description: The treatment was conducted using an Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55\* for tonsillar tissue ablation at low temperatures with only one treatment. All the patients underwent tonsil channeling treatment with coblation, and 4-6 channels were done in each tonsil under local anesthesia, in the operating room. The patients were observed overnight.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillectomy
Study: NCT01753804

Intervention type: OTHER
Intervention: Observational study
Description: There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
Study: NCT02320318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant 10 mg
Description: Oral tablet, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
Study: NCT02495012

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Freeze-dried powder without snake venom will be dissovled in saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anfibatide
Description: Freeze-dried powder with snake venom will be dissovled in saline
Study: NCT01982058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration
Study: NCT01464723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
Study: NCT01778777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Universe Reverse Prosthesis
Description: Implantation of an universe reverse prosthesis
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 matching placebo capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 matching placebo capsules
Description: Oral capsules
Study: NCT01336569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol maleate 0.5% fixed combination
Study: NCT03005938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.~SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Imitation of the spinal manipulation
Description: Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
Study: NCT01743456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted intra-operative depth of anaesthesia
Description: The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
Study: NCT03944434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: ribociclib 600 mg/day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors, non steroideal
Description: letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.
Study: NCT04042467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Greenlight Plus
Description: Families randomized to the Greenlight Plus arm will receive a HIT intervention starting at the newborn clinic visit. During the newborn visit, these families will receive basic instructions on how to access the Greenlight technology platform, which includes the iOTA text-messaging application and a website (usable on desktop or mobile platform). Families will receive text messages and goal-setting over the first 2 years of the child's life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Greenlight
Description: All residents and families seen in the participating clinics will receive the basic Greenlight materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Greenlight
Description: All residents and families seen in the participating clinics will receive the basic Greenlight materials.
Study: NCT01462201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Invasive Ultrasound
Description: Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Invasive Ultrasound
Description: Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.